Meeting
Abstract Number: 339
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Hydroxyurea is an FDA approved medication for use in adults with sickle cell disease. Clinical guidelines, based on high quality evidence, recommend its use in all adults with sickle cell anemia and 3 or more moderate to severe pain crises within one year. Studies suggest its use to be inappropriately low. We assessed local […]
Abstract Number: 381
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Sickle cell crisis is a acute medical emergency, which may require management in the ICU. Sickle cell anemias are remarkable in their clinical heterogeneity. Some people remain asymptomatic in their adult life, whereas others suffer repeated crisis; requiring multiple hospitalizations. In this study, we determine the demographic factors associated with a high readmission rate […]